Adjuvant Cisplatin and Docetaxel in Non Small Cell Lung Cancer
Completed · Phase 2
Conditions studied: Non Small Cell Lung Cancer
In brief
* To determine if docetaxel and cisplatin can be administered in a dose intense manner in the adjuvant setting in resected non-small cell lung cancer * To evaluate the time to progression and overall survival * To evaluate toxicities of this chemotherapy combination in the adjuvant setting * To correlate XPD and ERCC1 polymorphisms with time to progression and toxicities in patients treated with this regimen
Key facts
- Study ID
- NCT00582634
- Run by
- University of Wisconsin, Madison
- People needed
- 4
- Starts
- 2004-09-01
- Expected to finish
- 2007-12-01
- Last updated by the study team
- 2019-11-19
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Stage IB to IIIA non-small cell lung cancer completely resected within 4 to 8 weeks of initiating treatment on study
- Performance Status ECOG 0 or 1
- Peripheral neuropathy: < grade 1
- Adequate blood cell counts
- Adequate liver and hepatic function
- Women of childbearing potential must have a negative pregnancy test.
- Men and women of childbearing potential must be willing to consent to using effective contraception while on treatment and for at least 3 months thereafter
You may not qualify if…
- Patients with a history of severe hypersensitivity reaction to Docetaxel® or other drugs formulated with polysorbate 80.
- Women who are breast-feeding.
- Coexistent second malignancy or history of prior malignancy within previous 5 years (excluding basal or squamous cell carcinoma of the skin that has been treated curatively)
- Uncontrolled cardiac disease or uncontrolled hypertension
Where it is running
- University of Wisconsin Comprehensive Cancer Center — Madison, Wisconsin, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.